Perspectives of tumor-infiltrating lymphocyte treatment in solid tumors. 2021

Shuhang Wang, and Jingwei Sun, and Kun Chen, and Peiwen Ma, and Qi Lei, and Shujun Xing, and Zhongzheng Cao, and Shujun Sun, and Zicheng Yu, and Yarong Liu, and Ning Li
Clinical Cancer Center, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China.

Tumor-infiltrating lymphocyte (TIL) therapy is a type of adoptive cellular therapy by harvesting infiltrated lymphocytes from tumors, culturing and amplifying them in vitro and then infusing back to treat patients. Its diverse TCR clonality, superior tumor-homing ability, and low off-target toxicity endow TIL therapy unique advantages in treating solid tumors compared with other adoptive cellular therapies. Nevertheless, the successful application of TIL therapy currently is still limited to several types of tumors. Herein in this review, we summarize the fundamental work in the field of TIL therapy and the current landscape and advances of TIL clinical trials worldwide. Moreover, the limitations of the current TIL regimen have been discussed and the opportunities and challenges in the development of next-generation TIL are highlighted. Finally, the future directions of TIL therapy towards a broader clinical application have been proposed.

UI MeSH Term Description Entries
D008214 Lymphocytes White blood cells formed in the body's lymphoid tissue. The nucleus is round or ovoid with coarse, irregularly clumped chromatin while the cytoplasm is typically pale blue with azurophilic (if any) granules. Most lymphocytes can be classified as either T or B (with subpopulations of each), or NATURAL KILLER CELLS. Lymphoid Cells,Cell, Lymphoid,Cells, Lymphoid,Lymphocyte,Lymphoid Cell
D009369 Neoplasms New abnormal growth of tissue. Malignant neoplasms show a greater degree of anaplasia and have the properties of invasion and metastasis, compared to benign neoplasms. Benign Neoplasm,Cancer,Malignant Neoplasm,Tumor,Tumors,Benign Neoplasms,Malignancy,Malignant Neoplasms,Neoplasia,Neoplasm,Neoplasms, Benign,Cancers,Malignancies,Neoplasias,Neoplasm, Benign,Neoplasm, Malignant,Neoplasms, Malignant
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D016219 Immunotherapy, Adoptive Form of adoptive transfer where cells with antitumor activity are transferred to the tumor-bearing host in order to mediate tumor regression. The lymphoid cells commonly used are lymphokine-activated killer (LAK) cells and tumor-infiltrating lymphocytes (TIL). This is usually considered a form of passive immunotherapy. (From DeVita, et al., Cancer, 1993, pp.305-7, 314) Adoptive Cellular Immunotherapy,Adoptive Immunotherapy,CAR T-Cell Therapy,Cellular Immunotherapy, Adoptive,Chimeric Antigen Receptor Therapy,Immunotherapy, Adoptive Cellular,Adoptive Cellular Immunotherapies,Adoptive Immunotherapies,CAR T Cell Therapy,CAR T-Cell Therapies,Cellular Immunotherapies, Adoptive,Immunotherapies, Adoptive,Immunotherapies, Adoptive Cellular,T-Cell Therapies, CAR,T-Cell Therapy, CAR,Therapies, CAR T-Cell,Therapy, CAR T-Cell
D016246 Lymphocytes, Tumor-Infiltrating Lymphocytes that show specificity for autologous tumor cells. Ex vivo isolation and culturing of TIL with interleukin-2, followed by reinfusion into the patient, is one form of adoptive immunotherapy of cancer. Tumor Infiltrating Lymphocyte,Tumor-Derived Activated Cell,Tumor-Derived Activated Cells,Tumor-Infiltrating Lymphocyte,Tumor-Infiltrating Lymphocytes,Activated Cell, Tumor-Derived,Activated Cells, Tumor-Derived,Infiltrating Lymphocyte, Tumor,Infiltrating Lymphocytes, Tumor,Lymphocyte, Tumor Infiltrating,Lymphocyte, Tumor-Infiltrating,Lymphocytes, Tumor Infiltrating,Tumor Derived Activated Cell,Tumor Derived Activated Cells,Tumor Infiltrating Lymphocytes

Related Publications

Shuhang Wang, and Jingwei Sun, and Kun Chen, and Peiwen Ma, and Qi Lei, and Shujun Xing, and Zhongzheng Cao, and Shujun Sun, and Zicheng Yu, and Yarong Liu, and Ning Li
August 2022, Cancers,
Shuhang Wang, and Jingwei Sun, and Kun Chen, and Peiwen Ma, and Qi Lei, and Shujun Xing, and Zhongzheng Cao, and Shujun Sun, and Zicheng Yu, and Yarong Liu, and Ning Li
January 1994, Immunology series,
Shuhang Wang, and Jingwei Sun, and Kun Chen, and Peiwen Ma, and Qi Lei, and Shujun Xing, and Zhongzheng Cao, and Shujun Sun, and Zicheng Yu, and Yarong Liu, and Ning Li
January 2017, Klinicka onkologie : casopis Ceske a Slovenske onkologicke spolecnosti,
Shuhang Wang, and Jingwei Sun, and Kun Chen, and Peiwen Ma, and Qi Lei, and Shujun Xing, and Zhongzheng Cao, and Shujun Sun, and Zicheng Yu, and Yarong Liu, and Ning Li
December 2019, Sheng wu gong cheng xue bao = Chinese journal of biotechnology,
Shuhang Wang, and Jingwei Sun, and Kun Chen, and Peiwen Ma, and Qi Lei, and Shujun Xing, and Zhongzheng Cao, and Shujun Sun, and Zicheng Yu, and Yarong Liu, and Ning Li
January 2022, Frontiers in immunology,
Shuhang Wang, and Jingwei Sun, and Kun Chen, and Peiwen Ma, and Qi Lei, and Shujun Xing, and Zhongzheng Cao, and Shujun Sun, and Zicheng Yu, and Yarong Liu, and Ning Li
January 2022, Frontiers in immunology,
Shuhang Wang, and Jingwei Sun, and Kun Chen, and Peiwen Ma, and Qi Lei, and Shujun Xing, and Zhongzheng Cao, and Shujun Sun, and Zicheng Yu, and Yarong Liu, and Ning Li
January 2018, Cellular physiology and biochemistry : international journal of experimental cellular physiology, biochemistry, and pharmacology,
Shuhang Wang, and Jingwei Sun, and Kun Chen, and Peiwen Ma, and Qi Lei, and Shujun Xing, and Zhongzheng Cao, and Shujun Sun, and Zicheng Yu, and Yarong Liu, and Ning Li
January 1995, Immunologic research,
Shuhang Wang, and Jingwei Sun, and Kun Chen, and Peiwen Ma, and Qi Lei, and Shujun Xing, and Zhongzheng Cao, and Shujun Sun, and Zicheng Yu, and Yarong Liu, and Ning Li
January 2021, Oncoimmunology,
Shuhang Wang, and Jingwei Sun, and Kun Chen, and Peiwen Ma, and Qi Lei, and Shujun Xing, and Zhongzheng Cao, and Shujun Sun, and Zicheng Yu, and Yarong Liu, and Ning Li
June 2024, Oncology reports,
Copied contents to your clipboard!